Objective To explore the effects of amifostine on improving neurotoxicity induced by oxaliplat⁃in. Methods Ninty-six cases of patients with gastrointestinal cancers were randomly divided into observation group and control group, 48 patients in each group. The patients in the observation group were treated with oxali⁃platin combined with amifostine, but those in the control group were only treated with oxaliplatin. After 6 cycles of the treatment, the neurotoxicity of patients in two groups was evaluated. Results After 2, 4, 6 cycles of che⁃motherapy, the occurrence rates of grade 1~2 of peripheral neurotoxicity in the observed group was significant⁃ly lower than that of the control group[(10.41%)VS(50.00%),(14.58%)VS(58.33%),(6.26%)VS(68.75%), P<0.05]. The occurrence rates of grade 3~4 peripheral neurotoxicity in the observation group was also signifi⁃cantly lower than that of the control group[(4.17%)VS(29.17%),(6.25%)VS(25.00%), P<0.05]. The efficien⁃cy (Cr+PR) and the clinical benefit rate (Cr+PR+SD) in the observation group were higher than those in the con⁃trol group, [(79.17)%VS(83.33%);(87.50%)VS(91.67%)], but the difference was not statistically significant (P>0.05). Conclusion Amifostine can improve the neurotoxicity induced by oxaliplatin and have protective effect on peripheral nerve, while it will not reduce the clinical curative effect of oxaliplatin medicine.%目的：探讨氨磷汀改善奥沙利铂药物神经毒性的疗效。方法：选择96例胃肠道肿瘤患者，随机分为2组各48例，观察组给予奥沙利铂联合氨磷汀治疗，对照组仅给予奥沙利铂治疗，6个疗程后对两组神经毒性进行评估。结果：经2、4、6个周期的化疗，观察组1~2级神经毒性发生率分别为10.41%、14.58%、6.26%，明显低于对照组（50.00%、58.33%、68.75%）,P均<0.05。经4、6个周期的化疗观察组3~4级神经毒性发生率明显低于对照组（4.17%VS 29.17%,6.25%VS 25.00%, P均<0.05）；观察组有效率（CR+PR）为79.17%，临床受益率（CR+PR+SD）为87.50%，对照组分别为83.33%、91.67%，（79.17%VS 83.33%；87.50%VS 91.67%,χ2=0.274，0.447；P均>0.05）。结论：氨磷汀能预防奥沙利铂药物神经毒性，对周围神经产生保护作用，同时不会降低奥沙利铂类药物疗效。
展开▼
